<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05194163</url>
  </required_header>
  <id_info>
    <org_study_id>MW150-AD-201</org_study_id>
    <secondary_id>R44AG071388</secondary_id>
    <nct_id>NCT05194163</nct_id>
  </id_info>
  <brief_title>MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease</brief_title>
  <acronym>SKI-AD</acronym>
  <official_title>A Phase 2a Study of MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurokine Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Neurokine Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 2a randomized double-blind, placebo-controlled, study, in&#xD;
      mild-to-moderate Alzheimer's disease, of the oral investigational drug MW150, a p38alphaMAPK&#xD;
      kinase inhibitor. The primary goals of this study are to investigate the safety and&#xD;
      tolerability, and drug movements in the body. The secondary goals of the study are to&#xD;
      investigate the effects of the drug on cognitive performance, activities of daily living, and&#xD;
      behavior, and the biological effects of the drug on blood biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2022</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blind randomized placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Subjects will be randomized through a computerized system by a Data/Statistics Group independent from the investigator or Sponsor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Safety- Blood tests</measure>
    <time_frame>84 days treatment</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by laboratory test abnormalities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Safety- Electrocardiographic</measure>
    <time_frame>84 days treatment</time_frame>
    <description>Number of participants with emergent abnormal electrocardiograms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Safety- C-SSRS</measure>
    <time_frame>84 days treatment</time_frame>
    <description>Development of any suicidality on COLUMBIA-SUICIDE SEVERITY RATING SCALE (C-SSRS) score (minimum 0, no maximum, higher number worse).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Tolerability- Adverse events</measure>
    <time_frame>84 days treatment</time_frame>
    <description>Incidence of adverse events (AE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive change-MMSE</measure>
    <time_frame>84 days treatment</time_frame>
    <description>Change in MiniMental State Examination (MMSE) score (0-30, higher score better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive change-ADAScog</measure>
    <time_frame>84 days treatment</time_frame>
    <description>Change in Alzheimer's Disease Assessment Scale (ADAScog) score (0-70, higher score worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive change-Executive</measure>
    <time_frame>84 days treatment</time_frame>
    <description>Change in Trails A (0 - 150 sec) and Trails B test scores (0-300 sec), higher scores worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive change-Language</measure>
    <time_frame>84 days treatment</time_frame>
    <description>Change in Verbal Fluency tests for animals and letters (both minimum 0, no maximum, higher scores better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional performance- ADCS-ADL</measure>
    <time_frame>84 days treatment</time_frame>
    <description>Change in Alzheimers Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scale (0 - 78, higher score better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional performance-CDR</measure>
    <time_frame>84 days treatment</time_frame>
    <description>Change in Clinical Disease Rating Scale (0 - 3, higher score worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Scale - NPI-Q</measure>
    <time_frame>84 days treatment</time_frame>
    <description>Change in Neuropsychiatric Inventory Questionnaire (NPI-Q) (0-36, higher scores worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - cytokines</measure>
    <time_frame>84 days treatment</time_frame>
    <description>Changes in biomarker measurements of plasma levels of cytokines (IFN-γ, IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12P70, IL-22, and TNFα) by Simoa assay (pg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - neuronal biomarkers</measure>
    <time_frame>84 days treatment</time_frame>
    <description>Changes in biomarker measurements of plasma levels of tau protein and NfL protein by Simoa assay (pg/mL).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>10mg MW150 daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg MW150 daily (1 capsule of 10 mg daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo daily (1 capsule of matched placebo daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MW150</intervention_name>
    <description>oral-delivered capsule of study drug</description>
    <arm_group_label>10mg MW150 daily</arm_group_label>
    <other_name>MW01-18-150SRM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral delivered capsule matched to study drug capsule</description>
    <arm_group_label>placebo daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent from subject (or legally authorized representative, LAR) and&#xD;
             study partner.&#xD;
&#xD;
          2. Male or female, age 50 to 90 inclusive.&#xD;
&#xD;
          3. Have a study partner who is able to accompany the subject, has frequent contact with&#xD;
             subject.&#xD;
&#xD;
          4. Meet criteria for Alzheimer's Disease by NIAA-AA criteria.&#xD;
&#xD;
          5. Must speak English fluently.&#xD;
&#xD;
          6. Must have education of at least 8 years.&#xD;
&#xD;
          7. Must have adequate hearing and visual abilities.&#xD;
&#xD;
          8. MMSE score of 14 to 28.&#xD;
&#xD;
          9. Clinical Dementia Rating (CDR) Global score of 0.5 to 2.0 inclusive.&#xD;
&#xD;
         10. Absence of suicidal ideation for at least 1 year.&#xD;
&#xD;
         11. Absence of medical conditions that could affect ability to participate in study.&#xD;
&#xD;
         12. MRI within 1 year of screening, not showing clinically significant structural lesions.&#xD;
             Subjects without available MRI within 1 year, must have an MRI performed for&#xD;
             eligibility.&#xD;
&#xD;
         13. Stable neuropsychiatric medications for at least 2 months prior to screening.&#xD;
&#xD;
         14. If female, must not be of childbearing potential, as defined by being postmenopausal&#xD;
             (more than 1 year without periods) or surgically sterile for at least 6 months prior&#xD;
             to screening.&#xD;
&#xD;
         15. If male, must agree to use contraception if with a potentially childbearing partner.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of clinically significant disorders of the central nervous system other than&#xD;
             Alzheimer's disease, such as Lewy Body Disease, Parkinson's disease, hydrocephalus,&#xD;
             epilepsy, demyelinating disease, brain tumors, or psychiatric disorders (such as&#xD;
             schizophrenia, or severe affective disorders).&#xD;
&#xD;
          2. Serious or unstable hematologic, hepatic, renal, pulmonary, cardiac, or other medical&#xD;
             disease.&#xD;
&#xD;
          3. Abnormal liver function tests (ALT or AST) or creatine kinase (CK) upon repeat&#xD;
             testing.&#xD;
&#xD;
          4. Chronic hepatitis B or C infection, indicated by positive HBSAg, or HCV-Ab with HCV&#xD;
             RNA presence.&#xD;
&#xD;
          5. Known history of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          6. Known immune disorder that has a history of requiring treatment with immunosuppressive&#xD;
             drugs within the past 1 year.&#xD;
&#xD;
          7. Have a drug or alcohol abuse within 12 months prior to screening.&#xD;
&#xD;
          8. Clinically significant laboratory abnormalities at screening.&#xD;
&#xD;
          9. Screening ECG showing repeated QTcF &gt; 480 msec, or other clinically significant ECG&#xD;
             abnormalities.&#xD;
&#xD;
         10. Clinically significant structural brain abnormalities, such as hydrocephalus or&#xD;
             intra-axial brain tumors.&#xD;
&#xD;
         11. Participation in another investigational study within 30 days or 5 half-lives prior to&#xD;
             screening, whichever is greater.&#xD;
&#xD;
         12. Participation in another study that would have cognitive testing during the duration&#xD;
             of this study.&#xD;
&#xD;
         13. History of Covid19 or other viral infections within 3 months.&#xD;
&#xD;
         14. Have a clinically significant medical, surgical, laboratory, or behavioral&#xD;
             abnormality, which in the judgment of the Investigator makes the subject unsuitable&#xD;
             for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence S Honig, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lawrence S Honig, MD PhD</last_name>
    <phone>2123059194</phone>
    <email>lh456@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wayne P Anderson, PhD</last_name>
    <email>nkt.wanderson@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lawrence S Honig, MD PhD</last_name>
      <phone>212-305-9194</phone>
      <email>lh456@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Katrina Cuasay, AB</last_name>
      <phone>2123052077</phone>
      <email>kc2305@cumc.columbia.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2022</verification_date>
  <study_first_submitted>January 13, 2022</study_first_submitted>
  <study_first_submitted_qc>January 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2022</study_first_posted>
  <last_update_submitted>March 13, 2022</last_update_submitted>
  <last_update_submitted_qc>March 13, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Lawrence S Honig, MD, PhD, FAAN</investigator_full_name>
    <investigator_title>Professor of Neurology at Columbia University Irving Medical Center</investigator_title>
  </responsible_party>
  <keyword>p38alphaMAPK; dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Once study complete, de-identified participant data will be shared upon request by investigators from an academic institution.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>ICF will be shared at onset of enrollment. Study Protocol and SAP will be shared once study published. CSR will be shared once completed.</ipd_time_frame>
    <ipd_access_criteria>Protocol, SAP will be shared via publication. CSR will be shared upon request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

